Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more : results of a multicenter phase 3 study

  • Lo B
  • Beck J
  • Graux C
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Bob Lo

  • Joachim Beck

  • Carlos Graux

  • Wim Van Putten

  • Harry C Schouten

  • Leo F Verdonck

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free